Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline

Sam S. Chang, Stephen A. Boorjian, Roger Chou, Peter E. Clark, Siamak Daneshmand, Badrinath R. Konety, Raj Pruthi, Diane Z. Quale, Chad R. Ritch, John D. Seigne, Eila Curlee Skinner, Norm D. Smith, James M. McKiernan

Research output: Contribution to journalArticle

314 Scopus citations

Abstract

Purpose Although associated with an overall favorable survival rate, the heterogeneity of non-muscle invasive bladder cancer (NMIBC) affects patients’ rates of recurrence and progression. Risk stratification should influence evaluation, treatment and surveillance. This guideline attempts to provide a clinical framework for the management of NMIBC. Materials and Methods A systematic review utilized research from the Agency for Healthcare Research and Quality (AHRQ) and additional supplementation by the authors and consultant methodologists. Evidence-based statements were based on body of evidence strength Grade A, B, or C and were designated as Strong, Moderate, and Conditional Recommendations with additional statements presented in the form of Clinical Principles or Expert Opinions.1 Results A risk-stratified approach categorizes patients into broad groups of low-, intermediate-, and high-risk. Importantly, the evaluation and treatment algorithm takes into account tumor characteristics and uniquely considers a patient's response to therapy. The 38 statements vary in level of evidence, but none include Grade A evidence, and many were Grade C. Conclusion The intensity and scope of care for NMIBC should focus on patient, disease, and treatment response characteristics. This guideline attempts to improve a clinician's ability to evaluate and treat each patient, but higher quality evidence in future trials will be essential to improve level of care for these patients.

Original languageEnglish (US)
Pages (from-to)1021-1029
Number of pages9
JournalJournal of Urology
Volume196
Issue number4
DOIs
StatePublished - Oct 1 2016
Externally publishedYes

Keywords

  • cystectomy
  • drug therapy
  • immunotherapy
  • urinary bladder neoplasms

Fingerprint Dive into the research topics of 'Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline'. Together they form a unique fingerprint.

  • Cite this

    Chang, S. S., Boorjian, S. A., Chou, R., Clark, P. E., Daneshmand, S., Konety, B. R., Pruthi, R., Quale, D. Z., Ritch, C. R., Seigne, J. D., Skinner, E. C., Smith, N. D., & McKiernan, J. M. (2016). Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline. Journal of Urology, 196(4), 1021-1029. https://doi.org/10.1016/j.juro.2016.06.049